COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 43 of 81 for:    Baricitinib

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03742973
Recruitment Status : Completed
First Posted : November 15, 2018
Last Update Posted : October 22, 2019
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 26, 2019
Actual Study Completion Date : September 26, 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 18, 2020